Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial.

Publication Year: 2024

DOI:
10.2967/jnumed.123.266322

PMCID:
PMC10858380

PMID:
38071535

Journal Information

Full Title: J Nucl Med

Abbreviation: J Nucl Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Nuclear Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Evidence found in paper:

"the image-processing pipeline including the ai-based spleen segmentation feature extraction and survival analysis is publicly available at https://github com/kibromberihu/tumorlocationprofiler ."

Evidence found in paper:

"DISCLOSURE The REMARC clinical studies and analyses were sponsored by the Lymphoma Academic Research Organization (LYSARC) of France. Kibrom Girum and Irène Buvat received a research grant given to the Institut Curie by ANR (ANR-19-SYME-0005-03). Louis Rebaud was employed by Siemens Medical Solutions. No other potential conflict of interest relevant to this article was reported."

Evidence found in paper:

"The REMARC clinical studies and analyses were sponsored by the Lymphoma Academic Research Organization (LYSARC) of France. Kibrom Girum and Irène Buvat received a research grant given to the Institut Curie by ANR (ANR-19-SYME-0005-03). Louis Rebaud was employed by Siemens Medical Solutions. No other potential conflict of interest relevant to this article was reported."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025